Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
170 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00909025 | Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer | completed | Phase 1 | 15 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT01671774 | Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer(PILOT) | completed | Phase 1 | 29 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 14, 2024 |
| clinicaltrials |
| NCT04456699 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | completed | Phase 3 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Oct 29, 2024 | clinicaltrials |
| NCT02825628 | Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)(CRPC) | completed | Phase 2 | 55 | DexTech Medical ABINDUSTRY | 4 | Aug 29, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT05947903 | Validation of the European Oncology Quality of Life Toolkit | unknown | — | 4,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 32 | Aug 20, 2024 | clinicaltrials |
| NCT06473870 | Understanding Lung Cancer Related Risk Factors and Their Impact(LUCIA) | not yet recruiting | — | 6,160 | Biobizkaia Health Research InstituteOTHER_GOV | 3 | Jun 25, 2024 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT06275204 | H. Pylori Screen-and-treat Study in a Population of Young Adults | recruiting | — | 6,800 | University of LatviaOTHER | 6 | Mar 5, 2024 | clinicaltrials |
| NCT05073315 | A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis | completed | Phase 3 | 425 | AmgenINDUSTRY | 6 | Feb 9, 2024 | clinicaltrials |
| NCT03120949 | Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis(CREDO 4) | completed | Phase 3 | 2,106 | R-Pharm International, LLCINDUSTRY | 18 | Oct 12, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT01337089 | Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain | completed | Phase 3 | 660 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 12, 2023 | clinicaltrials |
| NCT00774930 | An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome(ELECT) | completed | Phase 3 | 115 | IpsenINDUSTRY | 11 | Oct 14, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT02432846 | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)(MERECA) | completed | Phase 2 | 88 | MendusINDUSTRY | 9 | Aug 22, 2022 | clinicaltrials |
| NCT02162667 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | completed | Phase 3 | 562 | CelltrionINDUSTRY | 22 | Aug 3, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT02200614 | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer(ARAMIS) | completed | Phase 3 | 1,509 | BayerINDUSTRY | 36 | Jun 28, 2022 | clinicaltrials |
| NCT05173077 | Hybrid-sensor Breath Analysis for Colorectal Cancer Screening(HYCOR) | unknown | — | 3,000 | University of LatviaOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02472964 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.(HERiTAge) | completed | Phase 3 | 500 | Mylan Inc.INDUSTRY | 15 | Feb 14, 2022 | clinicaltrials |
| NCT02630654 | Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs(EXPLAIN) | completed | — | 404 | IpsenINDUSTRY | 7 | Dec 7, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower150) | completed | Phase 3 | 1,202 | Hoffmann-La RocheINDUSTRY | 26 | Sep 23, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT04022109 | Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach(VOGAS) | recruiting | — | 5,000 | University of LatviaOTHER | 5 | Jul 26, 2021 | clinicaltrials |
| NCT02171429 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS II) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 19 | Jul 23, 2021 | clinicaltrials |
| NCT00545129 | A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone | completed | Phase 2 | 59 | PfizerINDUSTRY | 13 | Jun 18, 2021 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT00830180 | Open Label Extension In Cancer Patients | completed | Phase 2 | 41 | PfizerINDUSTRY | 10 | Apr 5, 2021 | clinicaltrials |
| NCT01784757 | Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer(ARAFOR) | completed | Phase 1 | 30 | Orion Corporation, Orion PharmaINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT02788214 | Helicobacter Pylori Genome Project (HpGP) | terminated | — | 1,000 | National Cancer Institute (NCI)NIH | 53 | Dec 19, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT01420588 | Diagnosis of Gastric Lesions From Exhaled Breath and Saliva | completed | — | 1,000 | Anhui Medical UniversityOTHER | 2 | May 8, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT00600340 | 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab(TURANDOT) | completed | Phase 3 | 564 | Central European Cooperative Oncology GroupOTHER | 12 | Dec 30, 2019 | clinicaltrials |
| NCT02344017 | Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer(DUALIDES) | completed | Phase 1 / Phase 2 | 23 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Dec 19, 2019 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials